



SelectImmune Pharma receives approval to conduct a placebo-controlled clinical study of Bladder Pain

SelectImmune Pharma is pleased to announce that the Swedish Medical Products Agency (Läkemedelsverket) has approved the application to conduct a placebo-controlled clinical study using IL1-RA for the treatment of Bladder Pain Syndrome.

Bladder pain syndrome is a highly painful chronic condition that severely impairs the quality of life of affected patients. Numerous therapeutic approaches have been tested, but currently, no specific therapies are available. Regular painkillers, or even morphine fails to provide adequate symptom relief and even after surgical removal of damaged parts of the bladder, the pain often returns.

We have recently reported positive treatment effects in this patient group, using the IL1- α and β receptor antagonist (IL1-RA) anakinra, reducing patient symptoms and increasing quality of life. The study also reported positive long-term effects, in patients who continue treatment.

SelectImmune Pharma is now proceeding with a randomized, placebo-controlled study of IL1-RA in patients with bladder pain syndrome. The company has received clinical trial authorization from the Swedish Medical Products Agency (Läkemedelsverket). The study is planned to involve several clinical sites.

“There is a clear unmet need, where current healthcare is only offering patients pain management and, as a last resort, surgical removal of the bladder” says Björn Wullt, docent, Lund University and senior urologist.

“Targeted immunotherapy offers a potentially important new molecular strategy to treat this difficult condition” says Gabriela Godaly, Professor, Lund University and CMO, SelectImmune Pharma.

For more information, please contact:

Catharina Svanborg

Chairman of the board SelectImmune Pharma AB

Phone: +46 709 42 65 49

E-mail: catharina.svanborg@med.lu.se

Gabriela Godaly

CMO SelectImmune Pharma AB

Phone: +46 733 38 13 44

E-mail: gabriela.godaly@med.lu.se

This disclosure contains information that SelectImmune is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 25-04-2022 09:50 CET.

SelectImmune Pharma is a pharmaceutical company whose shares are traded on the Spotlight Stock Market. The company's goal is to develop new immunotherapies, which act as immune enhancers and offer alternatives to antibiotics.

Bacterial infections affect large parts of the population and are becoming increasingly difficult to treat due to increasing antibiotic resistance. SelectImmune Pharma develops immunotherapies that can supplement or replace antibiotics. Urinary tract infections (UTI) are one of the world's most common infectious diseases, affecting about 150 million people each year. The need for alternative treatments for bacterial infections is currently very large as are potential markets.